An interventional study of Remogen and Cationorm in Dry Eye, sponsored by TRB Chemedica. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-20.
Sponsored by TRB Chemedica · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Dry Eye Syndromes with a site in France — 13 open to participants now, 14 under way, none of them phase 3. Dry Eye Syndromes · France.
Among the 47 studies in Dry Eye Syndromes with a site in France, this one is the 35th largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2018, is one of 28 with no phase, and was the 14th registered.
1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →13 of the 47 studies in Dry Eye Syndromes with a site in France are open now. Recruiting first, the newest first:
TRB Chemedica International SA · Sites in France, Belgium
Ages 18+
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
Ages 18+
TRB Chemedica International SA · Sites in France, Austria
Ages 18+
AbbVie · Sites in France, United States, Netherlands
Ages 18–75
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 60 across 1,131 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 81 across the 40 interventional studies, 45 across the 7 observational. Of the 29 that completed or were terminated, 12 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 47 have an industry lead sponsor. The 10 most frequent:
TRB Chemedica is the lead sponsor of 7 studies on the registry; none are open to participants now.
TRB Chemedica has 1 study filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
5 of the studies in Dry Eye Syndromes with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03358979Fondation Ophtalmologique Adolphe de RothschildThree-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE) | 2026-12 |
| NCT05865379TRB Chemedica International SAEfficacy and Safety of BUFY01 Versus SVS20 in the Treatment of Dry Eye Disease | 2027-04 |
| NCT05865457TRB Chemedica International SAEfficacy and Safety of BUFY02 Versus TRB02 in the Treatment of Dry Eye Disease | 2027-04 |
| NCT04129021Centre Hospitalier National d'Ophtalmologie des Quinze-VingtsHigh Resolution, High-speed Multimodal Ophthalmic Imaging | 2027-07 |
| NCT07844408Essilor InternationalStudy of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 47 studies in Dry Eye Syndromes with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The efficacy and safety of Remogen® Omega in the treatment of dry eye signs and symptoms will be investigated in comparison to Cationorm®.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: Remogen
Device: Cationorm
instil 1 drop of the product in each eye, 4 times per day
instil 1 drop of the product in each eye, 4 times per day
OSSF
Ocular surface staining with fluorescein (OSSF)
Time frame: Day 28
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2018 to primary completion in Apr 2019, 12 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
TRB Chemedica